RadioMedix.jpg
RadioMedix Inc. Announces the Acquisition of its 225Ac-PSMA I&T program, a Targeted Alpha Therapy (TAT) for Metastatic Castration Resistant Prostate Cancer, by Fusion Pharmaceuticals Inc.
15 févr. 2023 09h00 HE | RadioMedix Inc.
Houston, TX, Feb. 15, 2023 (GLOBE NEWSWIRE) -- RadioMedix, Inc. (“RadioMedix” or “Company”), a clinical-stage radiopharmaceutical company announced the acquisition of it’s 225Ac-PSMA-I&T asset...
RadioMedix.jpg
RadioMedix and Vect-Horus announce first dosing of Glioblastoma Multiforme and Pancreatic ductal adenocarcinoma patients with 68Ga-RMX-VH
15 nov. 2022 06h00 HE | RadioMedix Inc.
Houston, TX, USA and Marseille, France, Nov. 15, 2022 (GLOBE NEWSWIRE) -- RadioMedix and Vect-Horus are pleased to announce that they have successfully dosed the first patients in an exploratory...
RadioMedix.jpg
RadioMedix announces a $40 million Series A financing for the advancement of novel Targeted Alpha Therapy platform and diagnostic companion radiopharmaceuticals to address unmet needs in oncology; Michael Lee-Chin appointed to the board of the company
07 oct. 2022 18h11 HE | RadioMedix Inc.
HOUSTON and BURLINGTON, Ontario, Oct. 07, 2022 (GLOBE NEWSWIRE) -- RadioMedix, Inc. (“RadioMedix” or “Company”), a clinical-stage biotechnology company announced an agreement with an entity related...
Capture
Radiomedix and Orano Med Announce the Initiation of the Phase II Multi-Center Clinical Trial of Alphamedix™ for Targeted Alpha-Emitter Therapy of Neuroendocrine Cancers
03 janv. 2022 11h00 HE | RadioMedix Inc.
Houston, TX and Plano, TX, Jan. 03, 2022 (GLOBE NEWSWIRE) -- RadioMedix and Orano Med are pleased to announce the initiation of the Phase II clinical trial of AlphaMedix™ with the treatment of the...
radiomedix logo
RADIOMEDIX AWARDED $2.0 M NCI SBIR DIRECT-TO-PHASE II GRANT TO DEVELOP DRUG FOR TARGETED ALPHA-EMITTER THERAPY
18 nov. 2021 17h00 HE | RadioMedix Inc.
Houston, TX, Nov. 18, 2021 (GLOBE NEWSWIRE) -- RadioMedix, a clinical-stage biotechnology company developing radiotheranostic drugs, announced that it has been awarded a $2.0M Direct to Phase II...
radiomedix logo
Excel Diagnostics and Nuclear Oncology Center Announces FDA Authorization of IND for 225Ac-PSMA I&T Targeted Alpha Therapy for Castration Resistant Prostate Cancer
04 août 2021 07h00 HE | RadioMedix Inc.
Houston, TX, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Excel Diagnostics and Nuclear Oncology Center (EDNOC), a premier Diagnostic Imaging and Radioligand Therapy center in Houston, Texas announces approval...
techConnect award logo
RadioMedix wins 2020 TechConnect Innovation Award and pitched at Virtual TechConnect Business Summit
04 janv. 2021 11h00 HE | RadioMedix Inc.
Houston (TX), Jan. 04, 2021 (GLOBE NEWSWIRE) -- RadioMedix Inc. Houston-based clinical-stage radiopharmaceutical company is proud to announce that the company was selected for...
radiomedix logo
RadioMedix appointed Dr.Ferey Faridian as new member of the Board of Director
13 oct. 2020 05h00 HE | RadioMedix Inc.
Houston, TX, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Radiomedix a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and therapy of cancer,...
RMX and EXCEL
Excel Nuclear Oncology Center initiates the first Lu-177 DOTATOC PRRT clinical trial for the PUT-Neuroendocrine Tumors, in U.S.
24 févr. 2020 22h00 HE | RadioMedix Inc.
Houston, TX, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Excel Diagnostics and Nuclear Oncology Center (EDNOC) announced today that its physician sponsored Investigational New Drug (IND) application to...
OncoBeta® Tungsten (Wolfram)-188/Rhenium-188 (W/Re-188) Generator
RadioMedix and OncoBeta announce exclusive distribution agreement for W/Re-188 generators in U.S. and Canada
10 févr. 2020 16h00 HE | RadioMedix Inc.
Houston, TX, USA, and Garching, Germany, Feb. 10, 2020 (GLOBE NEWSWIRE) -- RadioMedix, and OncoBeta today announced the execution of an exclusive distribution agreement for the next generation of...